Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | CTSG | P08311 | 1/20 | 0.36 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
| ▸ | CTRC | Q99895 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2228270 | 0.86 | SIGMAR1 (0.56) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL1514871 | 0.76 | SIGMAR1 (0.50) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL688048 | 0.74 | SIGMAR1 (0.48) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL1936134 | 0.72 | SIGMAR1 (0.50) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL60814 | 0.71 | SIGMAR1 (0.74) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL18304983 | 0.71 | SIGMAR1 (0.43) | SIGMAR1MC4RDRD4LMNAPOLB | |
| Ammonia Solution, Strong SCHEMBL28160010 | 0.71 | SIGMAR1 (0.48) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL11564682 | 0.69 | SIGMAR1 (0.63) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL159371 | 0.68 | SIGMAR1 (0.61) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL276364 | 0.68 | SIGMAR1 (0.56) | SIGMAR1MC4RDRD4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
| US-6514970-B1 | Pyrrolidines such as benzo(b)thiophene-2-carboxylic acid ((S)-1-((S)-1-(4-(1-benzyl-piperidin-4-yloxy)-3-chloro-benzyl)-pyrrolidin-3 -ylcarbamoyl)-3- methyl-butyl)-amide | SMITHKLINE BEECHAM CORPORATION | 2003-02-04 | — | — | US | disclosed |
| EP-1187813-A1 | AZOLYLBENZAMIDES AND ANALOGUES AND THEIR USE FOR TREATING OSTEOPOROSIS | SMITHKLINE BEECHAM PLC (GB) | 2002-03-20 | — | — | EP | disclosed |
| WO-2001000587-A1 | AZOLYLBENZAMIDES AND ANALOGUES AND THEIR USE FOR TREATING OSTEOPOROSIS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | SIGMAR1 290/4885MC4R 993/4885DRD4 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.